Overview

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Status:
Completed

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening). Administration will be continued until the time of manufacturing and distribution approval of OPC-41061 for ADPKD in Japan.

Phase:

Phase 3

Details

Lead Sponsor:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Tolvaptan